Canada Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostic, Therapeutic), Application (Oncology, Bone Metastasis, Neurology, Cardiology), End-use (Hospitals & Clinics, Diagnostic Centers), Province, and Segment Forecasts, 2024-2030

1.1 Market Segmentation
1.1.1 Market Definitions
1.1.2 Estimates And Forecast Timeline
1.2 Objectives
1.2.1 Objective - 1
1.2.2 Objective - 2
1.2.3 Objective - 3
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.8 List of Secondary Sources
1.9 List of Abbreviations

2.1 Market Snapshot
2.2 Product and End-Use Segment Snapshot
2.3 Application Segment Snapshot
2.4 Competitive Landscape Snapshot

3.1 Canada Nuclear Medicine Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Incidence Of Cancer And Cardiovascular Diseases
3.2.1.2 Increasing Applications Of Radiopharmaceuticals/Nuclear Medicine
3.2.1.3 Growing Demand For Accurate Diagnostic Methods
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent Regulations Pertaining To Production, Storage, & Usage Of Nuclear Medicine & Radiopharmaceuticals
3.2.2.2 High Costs Associated With Diagnostics & Therapeutic Procedures
3.3 Canada Nuclear Medicine Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestle Analysis
3.4 Market Trends
3.4.1 Spect Radioisotopes Trends
3.4.2 Pet Radioisotopes Trends
3.4.3 Therapeutic Radioisotope Trends
3.5 COVID-19 Impact
3.6 Pipeline Analysis

4.1 Canada Nuclear Medicine Market: Product Movement Analysis
4.2 Canada Nuclear Medicine Market Estimates & Forecast, By Product (USD Million)
4.2.1 Diagnostic Products
4.2.1.1 SPECT
4.2.1.1.1 TC-99m
4.2.1.1.2 TL-201
4.2.1.1.3 GA-67
4.2.1.1.4 I-123
4.2.1.1.5 Other SPECT products
4.2.1.2 PET
4.2.1.2.1 F-18
4.2.1.2.2 SR-82/RB-82
4.2.1.2.3 Other PET products
4.2.2 Therapeutic Products
4.2.2.1 Alpha Emitters
4.2.2.1.1 RA-223
4.2.2.1.2 Others
4.2.2.2 Beta Emitters
4.2.2.2.1 I-131
4.2.2.2.2 Y-90
4.2.2.2.3 SM-153
4.2.2.2.4 Re-186
4.2.2.2.5 Lu-117
4.2.2.2.6 Other beta emitters
4.2.2.3 Brachytherapy
4.2.2.3.1 Cesium-131
4.2.2.3.2 Iodine-125
4.2.2.3.3 Palladium-103
4.2.2.3.4 Iridium-192
4.2.2.3.5 Other Brachytherapy Products

5.1 Canada Nuclear Medicine Market: Application Movement Analysis
5.2 Canada Nuclear Medicine Market Estimates & Forecast, by Application (USD Million)
5.2.1 Cardiovascular Disorders
5.2.2 Neurology
5.2.3 Oncology
5.2.4 Thyroid
5.2.5 Lymphoma
5.2.6 Bone Metastasis
5.2.7 Endocrine Tumor
5.2.8 Others

6.1 Canada Nuclear Medicine Market: End-Use Movement Analysis
6.2 Canada Nuclear Medicine Market Estimates & Forecast, By End Use (USD Million)
6.2.1 Hospitals & Clinics
6.2.2 Diagnostic Centers
6.2.3 Others

7.1 Canada
7.1.1 Alberta
7.1.2 Saskatchewan
7.1.3 Manitoba
7.1.4 Rest of Canada

8.1 Company Profiles
8.1.1 GE Healthcare
8.1.1.1 Company Overview
8.1.1.2 Financial Performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 Nordion (Canada), Inc.
8.1.2.1 Company Overview
8.1.2.2 Financial Performance
8.1.2.3 Product Benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 Lantheus Medical Imaging, Inc.
8.1.3.1 Company Overview
8.1.3.2 Financial Performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 Cardinal Health
8.1.4.1 Company Overview
8.1.4.2 Financial Performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic Initiatives
8.1.5 Jubilant Life Sciences Ltd.
8.1.5.1 Company Overview
8.1.5.2 Financial Performance
8.1.5.3 Product Benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 Isologic Innovative Radiopharmaceuticals
8.1.6.1 Company Overview
8.1.6.2 Financial Performance
8.1.6.3 Product Benchmarking
8.1.6.4 Strategic Initiatives
8.1.7 Curium Pharma
8.1.7.1 Company Overview
8.1.7.2 Financial Performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 adMare BioInnovations
8.1.8.1 Company Overview
8.1.8.2 Financial Performance
8.1.8.3 Product Benchmarking
8.1.8.4 Strategic Initiatives
8.2 Company Market Share Analysis, 2023

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Key products currently undergoing clinical trials
Table 4 Pipeline product status as on company website
Table 5 Canada Nuclear Medicine market revenue estimates and forecast, by product, 2018-2030 (USD Million)
Table 6 Canada Nuclear Medicine market revenue estimates and forecast, by application, 2018-2030 (USD Million)
Table 7 Canada nuclear medicine market revenue estimates and forecast, by end-use, 2018-2030 (USD Million)
Table 8 Company market share, 2023
Table 9 Key companies undergoing expansions
Table 10 Key companies undergoing collaborations
Table 11 Key companies undergoing new product launches
Table 12 Key companies undertaking acquisitions
Table 13 Key companies undertaking other activities

Figure 1 Canada Nuclear Medicine Market Segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Market snapshot
Figure 10 Product and end-use segment snapshot
Figure 11 Application segment snapshot
Figure 12 Competitive landscape snapshot
Figure 13 Pharmaceutical market value, 2023 (USD Billion)
Figure 14 Market dynamics
Figure 15 Most common cancer forms diagnosed in Canada, 2023
Figure 16 Porter’s Five Forces analysis
Figure 17 PESTLE analysis
Figure 18 Production of SPECT radioisotopes
Figure 19 Production of PET radioisotopes
Figure 20 Canada Nuclear Medicine market: Product outlook and key takeaways
Figure 21 Canada Nuclear Medicine market: Product movement analysis
Figure 22 Diagnostic products market estimates and forecast, 2018-2030 (USD Million)
Figure 23 SPECT market estimates and forecast, 2018-2030 (USD Million)
Figure 24 TC-99m market estimates and forecast, 2018-2030 (USD Million)
Figure 25 TL-201 market estimates and forecast, 2018-2030 (USD Million)
Figure 26 GA-67 market estimates and forecast, 2018-2030 (USD Million)
Figure 27 I-123 Market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Other SPECT products market estimates and forecast, 2018-2030 (USD Million)
Figure 29 PET market estimates and forecast, 2018-2030 (USD Million)
Figure 30 F-18 market estimates and forecast, 2018-2030 (USD Million)
Figure 31 SR-82/RB-82 market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Other PET products market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Therapeutic products market estimates and forecast, 2018-2030 (USD Million)
Figure 34 Alpha emitters market estimates and forecast, 2018-2030 (USD Million)
Figure 35 RA-223 market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Beta emitters market estimates and forecast, 2018-2030 (USD Million)
Figure 38 I-131 market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Y-90 market estimates and forecast, 2018-2030 (USD Million)
Figure 40 SM-153 market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Re-186 market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Lu-117 market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Other beta emitters market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Brachytherapy market estimates and forecast, 2018-2030 (USD Million)
Figure 45 Cesium-131 market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Iodine-125 market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Palladium-103 market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Iridium-192 market estimates and forecast, 2018-2030 (USD Million)
Figure 49 Other brachytherapy products market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Canada Nuclear Medicine market: Application outlook and key takeaways
Figure 51 Canada Nuclear Medicine market: Application movement analysis
Figure 52 Cardiovascular disorders market estimates and forecast, 2018-2030 (USD Million)
Figure 53 Neurology market estimates and forecast, 2018-2030 (USD Million)
Figure 54 Oncology market estimates and forecast, 2018-2030 (USD Million)
Figure 55 Thyroid market estimates and forecast, 2018-2030 (USD Million)
Figure 56 Lymphoma market estimates and forecast, 2018-2030 (USD Million)
Figure 57 Bone metastasis market estimates and forecast, 2018-2030 (USD Million)
Figure 58 Endocrine tumor market estimates and forecast, 2018-2030 (USD Million)
Figure 59 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 60 Canada nuclear medicine market: End-use outlook and key takeaways
Figure 61 Canada nuclear medicine market: End-use movement analysis
Figure 62 Hospitals & clinics market estimates and forecast, 2018-2030 (USD Million)
Figure 63 Diagnostic centers market estimates and forecast, 2018-2030 (USD Million)
Figure 64 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 65 Canada market estimates and forecast, 2018-2030 (USD Million)
Figure 66 Alberta market estimates and forecast, 2018-2030 (USD Million)
Figure 67 Saskatchewan market estimates and forecast, 2018-2030 (USD Million)
Figure 68 Manitoba market estimates and forecast, 2018-2030 (USD Million)
Figure 69 Rest of Canada market estimates and forecast, 2018-2030 (USD Million)
Figure 70 Key company categorization